D.E. Shaw & Co
MRSN

D.E. Shaw & Co’s Mersana Therapeutics MRSN Stock Holding History

D.E. Shaw & Co’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,000
Closed -$311K – 5798
2021
Q4 		$311K Hold
2,000
– – ﹤0.01% 4661
2021
Q3 		$472K Buy
+2,000
New +$584K ﹤0.01% 4120

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's MRSN Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 21,779 shares — an estimated $779K sold.

D.E. Shaw & Co first reported a position in MRSN in Q4 2017 and held it in 25 quarters. The position peaked at $24M in Q2 2020. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • D.E. Shaw & Co reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 21,779 Mersana Therapeutics shares in Q1 2025, an estimated $779K.
  • D.E. Shaw & Co first reported a position in Mersana Therapeutics in Q4 2017 and held it in 25 quarters.
  • D.E. Shaw & Co's Mersana Therapeutics position peaked at $24M in Q2 2020.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.